R.PR
REGISTERED-PRINCIPAL REGISTER
26/10/2021
Voltar para busca
Dado oficial do USPTO
RADX
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
RADX
ST13
US500000090226491Classe
35, 36, 41, 42
Pedido
90226491
Registro
6534475
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
20
Atualização mais recente
26/10/2021
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
35, 36, 41, 42
Data de depósito
30/09/2020
Data de registro
26/10/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
26/10/2021
Última transação
26/10/2021
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Primeiro uso
29/04/2020
Primeiro uso no comércio
29/04/2020
Código do desenho
4
Tipo de titular
99
Localização do titular
Bethesda, MD, US
Examinador
BAKER, JORDAN A
Unidade examinadora
O30
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
U.S. Department of Health and Human Services
Representantes
Angela Y. Dai OFFICE OF THE GENERAL COUNSEL
Classificação técnica
Classes Nice
Classe 35Classe 36Classe 41Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 35
Promoting researchdevelopmentvalidationcommercializationimplementation of testing technologies for pathogens; promoting researchdevelopmentvalidationcommercializationimplementation of testing technologies for viruses; promoting researchdevelopmentvalidationcommercializationimplementation of testing technologies for viruses that cause COVID-19 and influenza flu; promoting improvement of clinical laboratory testing technologies for COVID-19 and influenza flu; promoting researchdevelopmentvalidationcommercializationimplementation of testing technologies for pathogens through support of scientific organizationsresearch institutionsmedical institutionsacademic institutionsnon-profit organizationsbusiness entities; promoting researchdevelopmentvalidationcommercializationimplementation of testing technologies for viruses that cause COVID-19 and influenza flu through support of scientific organizationsresearch institutionsmedical institutionsacademic institutionsnon-profit organizationsbusiness entities; promoting collaboration within the scientificresearchmedicalacademicbusiness communities to advance researchdevelopmentcommercializationimplementation of testing technologies for pathogens; promoting collaboration within the scientificresearchmedicalacademicbusiness communities to advance researchdevelopmentcommercializationimplementation of testing technologies for viruses that cause COVID-19 and influenza flu; promoting collaboration within the technology innovatorclinical testingregulatory affairsentrepreneurbusiness leadercommunity leader networks to advance researchdevelopmentcommercializationimplementation of testing technologies for pathogens; promoting collaboration within the technology innovatorclinical testingregulatory affairsentrepreneurbusiness leadercommunity leader networks to advance researchdevelopmentcommercializationimplementation of testing technologies for viruses that cause COVID-19 and influenza flu; promoting community-engaged projects to assess and expand availability of testing technologies for pathogens in underserved and/or vulnerable populations; promoting community-engaged projects to assess and expand availability of testing technologies for viruses that cause COVID-19 and influenza flu in underserved and/or vulnerable populations; promoting collaboration between the scientific research community and underserved and/or vulnerable populations to achieve increased accessibility and availability of testing technologies for pathogens in underserved and/or vulnerable populations; promoting collaboration between the scientific research community and underserved and/or vulnerable populations to achieve increased accessibility and availability of testing technologies for viruses that cause COVID-19 and influenza flu in underserved and/or vulnerable populations; promoting rapid scale-up of testing technologies for pathogens; promoting rapid scale-up of testing technologies for viruses that cause COVID-19 and influenza flu; promoting increased availability of testing technologies for pathogens; promoting increased availability of testing technologies for viruses that cause COVID-19 and influenza flu; administration and management of research grants; administration of programs for promoting researchdevelopmentvalidationcommercializationimplementation of testing technologies for pathogens; administration of programs for promoting researchdevelopmentvalidationcommercializationimplementation of testing technologies for viruses that cause COVID-19 and influenza flu
Classe 36
Providing grants and financial support for biomedical research and development; providing grants and financial support for biomedical engineering; providing grants and financial support for researchdevelopmentvalidationcommercializationimplementation of testing technologies for pathogens; providing grants and financial support for researchdevelopmentvalidationcommercializationimplementation of testing technologies for viruses; providing grants and financial support for researchdevelopmentvalidationcommercializationimplementation of testing technologies for viruses that cause COVID-19 and influenza flu; providing grants and financial support for community-engaged projectsestablishment of clinical research sites and testing centers in underserved and/or vulnerable communities; providing information regarding funding opportunities relating to biomedical and scientific research and developments via a website
Classe 41
Providing a website featuring blogsnon-downloadable videosnon-downloadable videocastseducational presentations in the nature of seminarsforumsnon-downloadable webinars relating to medicalbiomedical and scientific research information and distribution of educational materials in connection therewith
Classe 42
Providing a website featuring medicalbiomedical and scientific research information; providing a website featuring news in the field of biomedical and scientific research and developments; providing a website featuring biomedical and scientific research information and developmentsdashboards displaying biomedical and scientific research datainformation and developments
Publicações
Histórico de despachos e eventos da marca no USPTO.
20 publicações encontradas
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/08/2021
PUBO
PUBLISHED FOR OPPOSITION
10/08/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
21/07/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/07/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
21/06/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
21/06/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
21/06/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
25/01/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
25/01/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
25/01/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
21/12/2020
GNRT
NON-FINAL ACTION E-MAILED
21/12/2020
CNRT
NON-FINAL ACTION WRITTEN
21/12/2020
DOCK
ASSIGNED TO EXAMINER
21/12/2020
PCGR
PETITION TO DIRECTOR GRANTED
18/12/2020
APET
ASSIGNED TO PETITION STAFF
17/12/2020
TPDR
TEAS PETITION TO DIRECTOR RECEIVED
16/11/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
14/11/2020
NWAP
NEW APPLICATION ENTERED
03/10/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace RADX ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.